Traws Pharma (TRAW) said Monday it entered agreements to raise up to $72.6 million through an equity offering.
An initial tranche of $20 million will involve the sale of around 3.9 million shares of common stock and pre-paid warrants, with an additional $52.6 million contingent on the exercise of non-prepaid warrants tied to upcoming bird flu data milestones in early and mid-2025, Traws Pharma said.
Closing is expected around Tuesday, the company said.
Traws Pharma shares plunged more than 37% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.